Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

June 02, 2021
https://clinicaltrials.gov/ct2/show/NCT04154072
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD

Parkinson Disease, Movement Disorders

Accepting Participants